Free Trial

Rocket Pharmaceuticals (RCKT) News Today

$20.94
-0.48 (-2.24%)
(As of 05/28/2024 ET)
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 525,452 shares o
Rocket Park assault leads to arrest
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Franklin Resources Inc.
Franklin Resources Inc. lifted its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 60.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,072,910 shares of the biotechnology company's stock after pu
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Westfield Capital Management Co. LP
Westfield Capital Management Co. LP trimmed its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,941,859 shares of the biote
Assenagon Asset Management S.A. Trims Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Assenagon Asset Management S.A. lessened its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 88.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,726 shares of the biotec
Q2 2024 EPS Estimates for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Decreased by Leerink Partnrs
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Leerink Partnrs reduced their Q2 2024 earnings per share estimates for Rocket Pharmaceuticals in a research note issued on Tuesday, May 7th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings
Rocket Pharmaceuticals (NASDAQ:RCKT) Releases Earnings Results, Beats Estimates By $0.01 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.01. During the same period in the previous year, the company posted ($0.73) EPS.
Needham & Company LLC Reaffirms Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
Needham & Company LLC restated a "buy" rating and issued a $53.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday.
Russell Investments Group Ltd. Has $19.45 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Russell Investments Group Ltd. decreased its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 648,946 shares of the bio
Rocket Pharmaceuticals Upgraded to Buy: Here's Why
Rocket Pharmaceuticals, Inc. (RCKT)
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy
Vontobel Holding Ltd. Purchases New Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Vontobel Holding Ltd. bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 43,540 shares of the
Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Write this ticker symbol down… (Ad)

A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.

Discover the #1 company leading this revolution

RCKT Media Mentions By Week

RCKT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RCKT
News Sentiment

0.17

0.79

Average
Medical
News Sentiment

RCKT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RCKT Articles
This Week

17

8

RCKT Articles
Average Week

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RCKT) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners